ReviewMaterials today. Bio2026
Erythrocyte-inspired biomaterials for cancer immunotherapy: Integration within the cancer-immunity cycle.
Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythrocyte-based drug delivery systems serve as an attractive strategy for cancer immunotherapy with improved biocompatibility, increased circulation time, and less immunogenicity. Due to their distinct physiological characteristics, erythrocytes can be developed as biomimetic carriers for targeted drug delivery, antigen presentation, and immune modulation. This review discusses the different strategies utilized to leverage erythrocytes in cancer immunotherapy, such as erythrocyte membrane-coated nanoparticles, antigen-hitchhiking systems, and immune-stimulatory erythrocyte-derived vesicles. Notably, we uniquely contextualizes erythrocyte-inspired platforms across each stage of the cancer-immunity cycle, highlighting their dual role as both drug delivery vehicles and active immunomodulators. We have explained how engineered erythrocyte-based systems enhance the cycle of cancer-immunity by increasing tumor antigen presentation and reshaping the tumor microenvironment for greater immune cell infiltration and cytotoxicity. In addition, recent advances in erythrocyte-based immunotherapeutic platforms, their advantages over conventional delivery platforms, and challenges in their clinical application are discussed. Overall, the integration of erythrocyte biomimetic technology into immunotherapy provides a novel approach to enhance cancer treatment efficacy and reduce systemic toxicity, paving the way for more targeted and effective therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.